Details of the Drug Reposition

General Information of This Drug (ID: DMFHV9L)

Drug Name
Leber's congenital amaurosis gene therapy   DMFHV9L
Synonyms LCA gene therapy, Applied Genetic Technologies; Leber's congenital amaurosis gene therapy, Applied Genetic Technologies; RAAV2-CB-hRPE65

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leber congenital amaurosis DISMGH8F 9B70 Phase 1/2 [1]
Visual disturbance DISKWKYH 9D90 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT00749957) Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health.